22 November 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
Gonzalo Sapisochin
1ADE*, Wei Chen Lee2ABCDE, Dong Jin Joo3ABD, Jae-Won Joh4ABE, Koichiro Hata 56BCDE, Arvinder Singh Soin7ACDE, Uday Kiran Veldandi8ABCDEF, Shuhei Kaneko9ACDE, Matthias Meier10ACDEG, Denise Leclair11DE, Gangadhar Sunkara11CDEF, Long Bin Jeng12AB
DOI: 10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
Table 6 Multivariate Cox regression analysis for time to HCC recurrence or death (ie, death by any cause or HCC recurrence, whichever occurred earlier; ITT population*).
| Parameter | Hazard ratio (95% CI) | P-value |
|---|---|---|
| Treatment: EVR+rTAC vs sTAC | 0.979 (0.323, 2.969) | 0.9702 |
| Milan Criteria: within vs beyond | 0.252 (0.072, 0.881) | 0.0309 |
| ESDCAT: non-HCC vs HCC | 1.119 (0.273, 4.596) | 0.8758 |
| Donor sex: male vs female | 0.378 (0.123, 1.163) | 0.0897 |
| Recipient sex: male vs female | 0.610 (0.153, 2.437) | 0.4840 |
| Diabetes at baseline: yes vs no | 1.191 (0.377, 3.766) | 0.7659 |
| MELD score: ≥15 vs ≤14 | 3.029 (0.957, 9.582) | 0.0594 |
| Race: White vs Asian | 1.246 (0.319, 4.873) | 0.7515 |
| Donor age (by 1 year) | 0.973 (0.921, 1.027) | 0.3224 |
| Recipient age (by 1 year) | 0.924 (0.870, 0.982) | 0.0108 |
| * Firth’s penalized maximum likelihood estimation was used. The interpretation of this multivariate analysis needs to consider few HCC recurrences or deaths in the data (only 7 and 10 for EVR and sTAC), and imbalance of some background factors due to which widths of CI have become large for some parameters. CI – confidence interval; ESDCAT – end-stage disease condition at transplant; EVR – everolimus; HCC – hepatocellular carcinoma; ITT – intent-to-treat; MELD – model for end-stage liver disease; rTAC – reduced-dose tacrolimus; sTAC – standard-dose tacrolimus. | ||